Multi4 wins CE mark for outpatient bladder cancer system

Multi4 Medical said it has received CE mark approval for its Multi4 System, clearing the bladder cancer device for commercialization in Europe. The company says the system is designed to let urologists detect and treat bladder tumors during the same outpatient visit, without using an operating room, general anesthesia, or hospitalization. In its announcement, Multi4 said the CE mark was supported in part by a clinical study at Sahlgrenska University Hospital in which 18 patients were treated with the system, and it noted the company had already received FDA clearance in the U.S. in 2025. (news.cision.com)

Why it matters: For veterinary professionals, the news is less about immediate clinical adoption and more about where minimally invasive oncology workflows may be heading. Bladder tumor management in both human and veterinary medicine can be resource-intensive, often requiring anesthesia, specialized equipment, and referral-level expertise. A platform that combines resection, coagulation, suction-based tissue removal, and injectable delivery in one system points to a broader push toward faster, lower-burden outpatient cancer procedures. Human urology guidelines already recognize limited office-based treatment for select small, low-grade recurrences, so this approval fits into a larger trend toward shifting appropriate bladder interventions out of the OR when safety and case selection allow. (accessdata.fda.gov)

What to watch: Watch for European rollout details, any published peer-reviewed clinical data beyond the company’s press materials, and whether the platform generates interest as a translational model for less invasive bladder tumor care in veterinary specialty practice. (news.cision.com)